Official Title
Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19
Brief Summary

The study is expected to treat patients with mild and severe neo-coronary pneumonia through standard treatment regimens in combination with tetrandrine tablets, thereby reducing the clinical progress of some patients, improving prognosis, reducing the incidence of pulmonary fibrosis during rehabilitation, and improving patients' quality of life.

Detailed Description

Since December 2019, a number of cases of pneumonia infected with the new coronavirus have
been found in wuhan, hubei province.Has now become a global epidemic of crisis.

After recent frontline anti-epidemic experience, the diagnostic and treatment specifications
for new coronary pneumonia have been updated several times. In the latest country,
"Specifications for the Diagnosis and Treatment of New Types of Coronary Pneumonia (Trial
Version 6)", the traditional Chinese medicines have again emphasized For the treatment of
patients, traditional Chinese medicine preparations such as Xuebijing and Qingfei Paidu
Decoction have been recommended, but the introduction of anti-fibrosis related drugs is still
lacking.Tetrandrine is a traditional Chinese medicine. Previous research has shown that it is
an antagonist of calmodulin, has anti-tumor, anti-inflammatory effects, and can effectively
inhibit fibroblasts, thereby inhibiting pulmonary fibrosis.The study is expected to treat
patients with mild and severe neo-coronary pneumonia through standard treatment regimens in
combination with tetrandrine tablets, thereby reducing the clinical progress of some
patients, improving prognosis, reducing the incidence of pulmonary fibrosis during
rehabilitation, and improving patients' quality of life.

Unknown status
Corona Virus Disease 2019,COVID-19

Drug: Tetrandrine

Tetrandrine 60mg QD for 1week
Other Name: tetrandrine tablets

Eligibility Criteria

Inclusion Criteria:

- Patients with mild and severe cases who have been diagnosed with new coronavirus
pneumonia according to the "Pneumonitis Diagnosis and Treatment -

- Plan for New Coronavirus Infection"

- Age 18 to 75 years;

- Sign the informed consent voluntarily.

Exclusion Criteria:

- With active tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma,
bronchiectasis, pulmonary embolism, patients with chronic respiratory failure or other
severe respiratory disease;

- According to the "pneumonia diagnosis and treatment program for new coronavirus
infection" (trial version 6), critically ill patients

- With severe patients with disease of heart head blood-vessel, malignant arrhythmia,
unstable angina, acute myocardial infarction and death, cardiac function level 3 and
above, stroke, cerebral hemorrhage, etc.);

- With severe liver and kidney diseases (severe liver disease refers to cirrhosis,
portal hypertension and varices bleeding, severe kidney disease including dialysis,
kidney transplantation);

- Pregnant and lactating women;

- Severe cognitive and mental disorders;

- Clinical investigators who were participating in other interventions within 1 month
prior to inclusion

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 75 Years
Countries
China
Locations

Tetrandrine Tablets
Jinhua, Zhejiang, China

Henan Provincial People's Hospital
NCT Number
Keywords
Covid-19
Tetrandrine
MeSH Terms
COVID-19
Virus Diseases
Tetrandrine